Adar1 Capital Management, Llc Purchases 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Keros Therapeutics Trading Up 2.7 %

Shares of KROS opened at $13.09 on Wednesday. The firm’s 50-day moving average is $10.97 and its two-hundred day moving average is $30.19. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37. The firm has a market capitalization of $530.96 million, a P/E ratio of -2.51 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KROS. AlphaQuest LLC grew its stake in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC grew its position in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Keros Therapeutics during the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC acquired a new position in shares of Keros Therapeutics during the 4th quarter worth approximately $99,000. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KROS. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Truist Financial cut their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Oppenheimer cut their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Finally, Scotiabank lowered their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.